Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pirtobrutinib + R-CHOP
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Pirtobrutinib + R-CHOP is an investigational combination regimen consisting of the next-generation, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib and the standard-of-care immunochemotherapy regimen R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). This combination is primarily being evaluated for the first-line treatment of newly diagnosed non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL). Pirtobrutinib, developed by Eli Lilly, inhibits BTK, a critical node in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells, particularly in the non-GCB/ABC subtype of DLBCL. By combining a reversible BTK inhibitor with the cytotoxic and immunotherapeutic components of R-CHOP, the regimen aims to overcome constitutive BCR signaling and improve clinical outcomes compared to standard immunochemotherapy alone.
- Brand names
- JaypircaRituxanMabThera
- Other names
- pirtobrutinib plus R-CHOPpirtobrutinib, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
02
Targets
BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on pirtobrutinib + R-CHOP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pirtobrutinib + R-CHOP.